Research Article

PREPARATION AND CHARACTERIZATION OF β-CYCLODEXTRIN INCLUSION COMPLEXES ORAL TABLETS CONTAINING POORLY WATER SOLUBLE GLIMIPRIDE USING FREEZE DRYING METHOD

Yandi Syukri*, Laryssa Fernenda, Fissy Rizki Utami, Isna Qftayati, Aris Perdana Kusuma, Rochmy Istikaharah

Department of Pharmacy, Universitas Islam Indonesia, Jalan Kaliurang KM 14,5 Sleman Yogyakarta, 55584, Indonesia

Submitted: 25-12-2014
Revised: 15-01-2015
Accepted: 25-02-2015

*Corresponding author
Yandi Syukri

Email: yandi.sy@gmail.com

ABSTRACT

Glimepiride is an oral antidiabetic drugs which is practically insoluble in water. The formation of β-cyclodextrin inclusion complex was able to increase the solubility of glimepiride. This study aim to prepare, characterize and formulation of inclusion complex tablets in order to meet the requirement in Pharmacopeia. The inclusion complex were prepared in a molar ratio of 1:1 and 1:2 by freeze drying method, after that characterized include FTIR spectroscopy and scanning electro microscope (SEM). Further, it was formulated into tablets by direct compression technique using primogel and crospovidone as super disintegrants. The tablets were evaluated include weight uniformity, hardness, friability, disintegration, and dissolution. The dissolution studies of inclusion complex were performed by using USP II apparatus. The result of FTIR and SEM provided evidence of the formation of complexes after utilizing freeze-drying methods. The tablet evaluation containing inclusion complex glimepiride–β cyclodextrin with primogel and crospovidone as disintegrant showed that increased concentration of disintegrant will increase disintegration time of the tablets. All of formulas meet the requirements in the Pharmacopoeia. The inclusion complex of glimepiride–β cyclodextrin successfully used for enhancing the solubility of glimepiride and the tablets meet the requirement in Pharmacopeia.

Keywords: Glimepirid, β-cyclodextrin, primogel, crospovidone

INTRODUCTION

The oral administration of drug is the most used to drug delivery in pharmacy due to its ease of administration, convenient, cost-effectiveness and flexibility in design (Krishnaiah, 2010). Poor bioavailability of the drug is a major disadvantage of oral drug delivery due to low aqueous solubility and low drug permeability (Savjani et al., 2012). The poorly water soluble drug indicate low absorption and bioavailability is often controlled by the rate of dissolution of the drug in the gastrointestinal tract. Many approach has been done for enhancing the dissolution characteristics of slightly water-soluble drugs included reduce particle size, crystal modification, cyclodextrin complexation and self-emulsification (Kawabata et al., 2011). Solid dispersion also has been reported to increase dissolution of disulfiram and indomethacin (Ramadhani et al., 2014; Sunil et al., 2012).

Based on the various methods, cyclodextrin complexation has gained good acceptance in recent years in industry for enhancing the solubility and dissolution rate of poorly soluble drugs (Saravana Kumar et al., 2013). Cyclodextrin complexation has shown promising results in improving solubility, wettability, dissolution rate of drug and subsequently its bioavailability of products that are orally administered (Shanmuga Priya et al., 2013). Cyclodextrin have been developed to oral drug delivery for different objectives including reduction of gastrointestinal tract (GIT) irritation, unpleasant taste masking, and improvement of drug bioavailability through enhancement of the solubility and dissolution rate, and/or increased stability of the drug at the absorption site in the GIT (Challa et al.,...
Preparation and Characterization of β-Cyclodextrin

2005). Recently, complexation with cyclodextrins has been reported to enhance the solubility and dissolution rate of itraconazole (Taupitz et al., 2013), curcumin (Michel et al., 2012), repaglanide (Liu et al., 2014), and myricetin (Yao et al., 2014).

The preparation methods of cyclodextrin inclusion compound commonly used are co-precipitation method, ultrasonic method, grinding method, spray-drying method, and freeze-drying method (Lee et al., 2010). The inclusion complexes omeprazole prepared with freeze-drying method produces true inclusion complexes better than subtherapeutic plasma drug levels (Figueiras et al., 2007).

Glimepiride is one of the third generation sulfonylurea drugs useful to control of diabetes mellitus type 2 (Ammar et al., 2006). It has poor solubility and slow dissolution rate in water and a pH-dependent solubility as well. Glimepiride is classified under class II according to biopharmaceutical classification system (Frick et al., 1998). This may lead to irreproducible clinical response or therapeutic failure in some cases due to subtherapeutic plasma drug levels (Reven et al., 2010). Until now, the published results on glimepiride solubility improvement have involved microencapsulation of glimepiride by spray congealing technology using hydrophilic melttable carriers (Ilić et al., 2009) and nanocrystal to reduce particle size and stability (Sajeev et al., 2013).

The objective of present study is to prepare inclusion complex of glimepiride with cyclodextrins in different molar ratios by freeze drying method. The inclusion complex was further formulated into tablets by direct compression technique using superdisintegrants primogel and crospovidone in order to increase the solubility of glimepiride for improvement of dissolution rate of the drug in the prepared tablet formulations.

MATERIAL AND METHODS

Glimepiride was obtained from Cross Chem International Company Switzerland, β-cyclodextrin from Signa Husada Ltd. Company Indonesia., crospovidone from Dexta Medika Ltd. Company Indonesia and all other excipients such as primogel, aerosil, avicel PH-102, and magnesium stearate were given from Pharmaceutical Technology Laboratory Universitas Islam Indonesia. All materials used are of pharmacopeial grade.

Preparation of β - cyclodextrin inclusion complexes

The preparation of inclusion complex was employed by freeze drying method using freeze dryer Alpha 1-2 LD plus models. Glimepiride with β - cyclodextrin in different molar ratios (i.e. 1:1M. 1:2M) were dispersed in ethanol using a laboratory stirrer for 48h at room temperature (25°C) to allow for complex formation and prevent loss of volatiles to the atmosphere. The solution was frozen at -20°C and lyophilized at -50°C. The lyophilized samples were stored in sealed containers inside a desiccators (Santos et al., 2015).

FTIR spectroscopy

FTIR spectroscopy (Nicolet Avatar 360) was used to study the molecular structures of the samples in the wave number range of 400-4000cm⁻¹. The glimepiride, β-cyclodextrin and inclusion complexes glimepiride-β-cyclodextrin were diluted with KBr mixing powder at 1% and pressed into transparent slices to be analyzed.

Scanning Electron Microscopy

SEM (jeol JSTM T300 models) was employed to analyze the particle shape of raw glimepiride, raw β-cyclodextrin and inclusion complex of glimepiride-β-cyclodextrin. Each dry sample was mounted on aluminum stubs using double sided carbon tape and sputter-coated with gold under an argon atmosphere. Then the particle shape and size of each sample was observed and analyzed.

Preparation of tablets

The complex of glimepiride-β-cyclodextrin was prepared into tablet by direct compression method containing 2mg of glimepiride. The complex and all ingredients were properly mixed together. The mixed blend of drug and excipients was then compressed in to tablet by using single punch tablet compression machine (Korsh EK 0). The composition of different tablet formulations are shown in table 1.
Table I. Formulae for preparation of glimepiride – β-cyclodextrin (1 : 1 M) inclusion complex tablets with primogel and crospovidone as disintegrant (quantity for 1 tablet).

<table>
<thead>
<tr>
<th>Ingredients (code for complex)</th>
<th>F1</th>
<th>F2</th>
<th>F3</th>
<th>F4</th>
<th>F5</th>
<th>F6</th>
<th>F7</th>
<th>F8</th>
<th>F9</th>
<th>F10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glimepiride–β-cyclodextrin inclusion complexes (mg)</td>
<td>14.7</td>
<td>14.7</td>
<td>14.7</td>
<td>14.7</td>
<td>14.7</td>
<td>14.7</td>
<td>14.7</td>
<td>14.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primojel (mg)</td>
<td>2</td>
<td>3.5</td>
<td>5</td>
<td>6.5</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Crospovidone (mg)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>2.75</td>
<td>3.5</td>
<td>4.25</td>
<td>5</td>
</tr>
<tr>
<td>Avicel pH 102 (mg)</td>
<td>81.3</td>
<td>79.8</td>
<td>78.3</td>
<td>76.8</td>
<td>75.3</td>
<td>81.3</td>
<td>80.5</td>
<td>79.5</td>
<td>79.1</td>
<td>78.3</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Aerosil (mg)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Total quantity (mg)</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>

**Evaluation of tablet**

The prepared tablets were evaluated for weight variation, hardness, friability, and disintegration time. The USP weight variation test is done by weighing 20 tablets individually, calculating the average weight and comparing the individual weights to the average. The hardness of 10 tablets was determined using the Erweka hardness tester. Friability was determined by first weighing 10 tablets after dusting and placing them in a friability tester (Erweka TA 200), which was rotated for 4 min at 25rpm. After dusting, the total remaining mass of tablet was recorded and the percent friability was calculated. Disintegration times of six tablets per formulae were individually determined in a disintegration tester (Erweka ZT 502) containing aquades at 37±0.5°C. The mean disintegration times were calculated.

**In vitro dissolution tablets**

In *vitro* dissolution of tablet was studied in USP XXIV dissolution apparatus (Erweka 708) employing a paddle stirrer in 900L of phosphate buffer of pH 7.4 as dissolution medium. The stirrer was adjusted rotate at 75rpm. The temperature of dissolution media was maintained to 37±0.5°C. After that, 5mL of sample of dissolution medium were withdrawn by means of syringe fitted with pre-filter at known intervals of time and analyzed for drug release by measuring the absorbance at 227nm. The volume withdrawn at each time interval was replaced with fresh quantity of dissolution medium. Percentage amount of glimepiride released was calculated and plotted against time.

**RESULTS AND DISCUSSION**

**FTIR spectroscopy**

FTIR spectroscopy is a useful technique to confirm the formation of solid state inclusion complexes because the corresponding peak intensities of the included part of the guest molecules generally get shifted, reduced or sometimes they disappeared. FTIR Spectra of pure drug, β-cyclodextrin and inclusion complexes of glimepiride with β-cyclodextrin 1:1 and 1:2 results shown in figure 1.

FTIR spectra inclusion complexes 1:1 and 1:2 M showed that reduced absorption band O-H β-siklodekstrin from 3385.46cm⁻¹ to 3371.27 and 3371.49cm⁻¹. This can be not only due to the vibration frequency of the O-H bond of β-cyclodextrin, but also due to the influence of hydrogen bonding with the group C=O on glimepiride. This is the reason for the decline in vibration frequency indicated by the peak of C=O and O-H are declining at an inclusion complex of 1:1 and 1:2 M. Inclusion complexes 1:1 and 1:2 M also reduced absorption band C=O of glimepiride from 1674.0cm⁻¹ to 1669.56cm⁻¹ dan 1669.47cm⁻¹. Molecular interactions between the glimepiride-β-cyclodextrin can occur through hydrogen bonding and Van der Waals bonding. Hydrogen bonding will occur between polar compounds with β-cyclodextrin glimepiride. Van der Waals bonding will occur between non-polar compounds with glimepiride-β-cyclodextrin.

The above data proved that there has been the formation of complexes between glimepiride-β-cyclodextrin with a weak bond.
The interaction occurred was only physical contact between glimepiride and β-cyclodextrin molecules, therefore chemical structure of glimepiride unchanged. Recrystallization glimepiride and β-cyclodextrin simultaneously occurred in the process of freeze drying causes glimepiride will be entered into β-cyclodextrin cavities to formed inclusion complexes.

**Scanning Electron Microscopy.**

Figure 2 showed that, glimepiride has been covered by β-cyclodextrin after mixing process using freeze drying method. Glimepiride was originally flake-shaped surface. The shape changed after a complex process using β-cyclodextrin inclusion into an amorphous. The shape of the slab has become...
Table II. Evaluation of tablets containing glimepiride-β-cyclodextrin inclusion complex 1 : 1 M.

<table>
<thead>
<tr>
<th>Formulation Code</th>
<th>Weighted average (mg)</th>
<th>Hardness (kg)</th>
<th>Friability (%)</th>
<th>Disintegration time (sec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>102.05±1.19</td>
<td>4.91±0.35</td>
<td>0.06±0.03</td>
<td>37.33±2.31</td>
</tr>
<tr>
<td>F2</td>
<td>101.45±0.89</td>
<td>5.28±0.26</td>
<td>0.03±0.03</td>
<td>30.00±1.00</td>
</tr>
<tr>
<td>F3</td>
<td>99.10±1.07</td>
<td>4.34±0.14</td>
<td>0.05±0.00</td>
<td>27.33±2.31</td>
</tr>
<tr>
<td>F4</td>
<td>98.15±0.93</td>
<td>5.51±0.18</td>
<td>0.05±0.00</td>
<td>26.67±1.16</td>
</tr>
<tr>
<td>F5</td>
<td>100.80±1.54</td>
<td>5.41±0.29</td>
<td>0.07±0.03</td>
<td>24.33±0.58</td>
</tr>
<tr>
<td>F6</td>
<td>102.35±2.75</td>
<td>5.32±0.36</td>
<td>0.01±0.00</td>
<td>72.33±2.08</td>
</tr>
<tr>
<td>F7</td>
<td>101.20±2.58</td>
<td>5.27±0.35</td>
<td>0.01±0.00</td>
<td>28.00±0.82</td>
</tr>
<tr>
<td>F8</td>
<td>102.60±1.63</td>
<td>4.72±0.29</td>
<td>0.01±0.00</td>
<td>27.67±0.94</td>
</tr>
<tr>
<td>F9</td>
<td>103.35±1.42</td>
<td>5.18±0.35</td>
<td>0.01±0.00</td>
<td>24.67±1.25</td>
</tr>
<tr>
<td>F10</td>
<td>103.90±1.17</td>
<td>4.97±0.45</td>
<td>0.01±0.00</td>
<td>23.33±1.89</td>
</tr>
</tbody>
</table>

Figure 3. Dissolution profile of inclusion complex tablets with primogel as disintegrant

Figure 4. Dissolution profile of inclusion complex tablets with crospovidone as disintegrant
increasingly apparent in the inclusion complex of 1:2M. This can be due to the inclusion complex of 1:2M contains concentrations of β-cyclodextrin are more than the inclusion complex of 1:1M. The above figure proved that the inclusion complexes formed during recrystallization of glimepiride and β-cyclodextrin causing glimepiride entering into hydrophobic cavity of β-cyclodextrin.

**Evaluation of tablet**

Table II showed that a good degree of uniformity of weight for all formulations prepared. It is also clear from the tables that all the tablets exhibited good mechanical properties with regard to both hardness and friability. Disintegration time showed that, the increased of primogel and crospovidone concentration will increased time for disintegration of the tablets. This finding can be explained by the fact that primogel have rapid water absorption followed by the ability of a high swell when exposed to water so that the particles making up the tablet broke and can accelerate the disintegration time of tablets. The more concentration primogel used the faster tablets disintegrate. Crospovidone having a porous particle morphology to facilitate water enters the capillary action (wicking) and its rapid return to the initial structure after expands create increased hydrostatic pressure so as to accelerate the process of disintegration. The above data also shows that the ability of primogel and crospovidone have relatively equal good disintegrant, although each has a different mechanism.

**In vitro dissolution studies**

As shown in figure 3 and 4, the primogel and crospovidone as disintegrant in tablet formulation had similarity effects on dissolution profile. The inclusion complexes tablet showed that the glimepiride immediately released with high dissolution rate. United State Pharmacopeia (USP) 32 presupposed that glimepiride tablets must be dissolved not less than 80% within 45min of the amount stated on the label. The dissolution results showed that all formulas fulfil Pharmacopeia requirement.

Dissolution test data indicated that primogel and crospovidone can be used as disintegrant in tablet formulations containing poorly soluble glimepiride with β-cyclodextrin inclusion complexes. In addition to meet the requirements of pharmacopeia, inclusion complexes tablet glimepiride–β-cyclodextrin also showed immediately drug released because 80% of drug has been released before 10min.

**CONCLUSIONS**

The β-cyclodextrins can be used to prepare inclusion complex of glimepiride with improved solubility of the drug by freeze drying method. All inclusion complexes tablet produced good quality and meet the requirement of pharmacopeia. The inclusion complexes tablets also showed high drug release indicated by dissolution profile.

**ACKNOWLEDGEMENTS**

The authors are thankful to Pharmaceutical Laboratory, Department of Pharmacy Universitas Islam Indonesia for providing the facilities to carry out the work.

**REFERENCES**


**Preperation and Characterization of β-Cyclodextrin**


